Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-18T13:16:38.525Z Has data issue: false hasContentIssue false
  • English
  • Français

MTHFR gene polymorphism, homocysteine and cardiovascular disease

Published online by Cambridge University Press:  27 September 2007

Claudio Cortese  and
Corradino Motti
Claudio Cortese*
Affiliation:
Department of Internal Medicine, University of Tor Vergata, Via di Tor Vergata 135, 00133 Rome, Italy
Corradino Motti
Affiliation:
Institute of Biochemistry and Molecular Biology, University of Teramo, Italy
*
*Corresponding author: Email [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Homocysteine is an emerging new risk factor for cardiovascular disease. It is a thiol compound derived from methionine and involved in two main metabolic pathways: the cycle of activated methyl groups, requiring folate and vitamin B12 as cofactors, and the transsulfuration pathway to cystathionine and cysteine requiring vitamin B6 as cofactor. The homocysteine metabolism represents an interesting model of gene-environment interaction. Elevations in homocysteine may be caused by genetic defects in enzymes involved in its metabolism or by deficiencies in cofactor levels. A common polymorphism in the gene coding for the 5, 10-methylene tetrahydrofolate reductase (MTHFR) (C677T, Ala → Val) is associated with a decreased activity of the enzyme due to thermolability. In case of homozygosity for the Val allele, a relative deficiency in the remethylation process of homocysteine into methionine leads to a mild-to-moderate hyperhomocysteinemia, a condition recognized as an independent risk factor for atherosclerosis. The genetic influence of the MTHFR polymorphism on homocysteine levels is attenuated in females in premenopausal age and is not significant in subjects who exhibit serum levels of folate and/or vitamin B12 above the 50th percentile of distribution in the general population. The prevalence of the Val/Val genotype varies among different ethnic groups. It is very low in African populations, whereas in Europe and North America it ranges between 5% and 15%. In Italy an even higher prevalence has been reported in some regions. The question whether the MTHFR polymorphism might be per se an independent contributor to cardiovascular risk is debated. The interaction between this or other genetic factors and environmental/nutritional conditions (i.e. intake of vitamins such as folate) is a key determinant for homocysteine concentrations in healthy conditions as well as in some disease (i.e. in renal disorders). Another example of gene/environment interaction in the field of atherosclerosis is given by the apolipoprotein E polymorphism and its influence in response to diet. The presence of a high prevalence of risk-related allelic variants of such candidate genes within a certain population could serve to locally reinforce the recommendations concerning nutrient intake.

Keywords

HomocysteineFolateCardiovascular diseaseMethylene TetrahydrofolatereductasePolymorphismApolipoprotein E
Type
Research Article
Information
Public Health Nutrition , Volume 4 , Issue 2b , April 2001 , pp. 493 - 497
Copyright
Copyright © CABI Publishing 2001

References

1Welch, GN, Lo Scalzo, J.Homocysteine and atherothrombosis. N. Engl. J. Med. 1998; 338: 1042–50.CrossRefGoogle ScholarPubMed
2Kang, SS, Wong, PWK, Susmano, A, Sora, H, Norusis, M, Ruggie, N.Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary heart disease. Am. J. Hum. Genet. 1991; 48: 536–45.Google Scholar
3Frosst, P, Blom, HJ, Milos, R, Goyette, P, Sheppard, CA, Matthews, RG, Boers, GJH, den Heijer, M, Kluijtmans, LAJ, van den Heuvel, LP, Rozen, R.A candidate gene risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 1995; 10: 111–3.CrossRefGoogle Scholar
4Jacques, PF, Bostom, AG, Williams, RR, Ellison, RC, Eckfeldt, JH, Rosenberg, IH. Selhub, J. Rozen, R.Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7–9.CrossRefGoogle ScholarPubMed
5Fletcher, O, Kessling, AM. MTHFR association with arteriosclerotic vascular disease? Hum. Genet. 1998; 103: 11–21.CrossRefGoogle ScholarPubMed
6Pepe, G, Camacho Vanegas, O, Giusti, B, Brunelli, T, Marcucci, R, Attanasio, M, Rickards, O, De Stefano, GF, Prisco, D, Gensini, GF, Abbate, R.Heterogeneity in World Distribution of the Thermolabile C677T mutation in 5, 10-methylenetetrahydrofolate reductase. Am. J. Hum. Genet. 1998; 63: 917–20.CrossRefGoogle Scholar
7Gudnasson, V, Stansbie, D, Scott, J, Bowron, A, Nicaud, V, Humphries, S. on behalf of the EARS group. C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. Atherosclerosis 1988; 136: 347–54.CrossRefGoogle Scholar
8Nygard, O, Refsum, H, Ueland, PM, Stensvold, I, Nordrehaug, JE, Kvale, G, Vollset, SE. Coffee consumption and plasma total homocysteine: The Hordaland, Homocysteine Study. Am. J. Clin. Nutr. 1997; 65: 136–43.CrossRefGoogle ScholarPubMed
9Stolzenberg-Solomon, RZ, Miller, ER 3rd, Maguire, MG, Selhub, J, Appel, LJ. Association of dietary protein intake and coffee consumption with serum homocysteine concentrations in an older population. Am. J. Clin. Nutr. 1999; 69:467–75.CrossRefGoogle Scholar
10Food Standards. Amendment of standards of identity for enriched grain products to require addition of folic acid. Federal Register 1996; 61: 8781–97Google Scholar
11Jacques, PF, Selhub, J, Bostom, AG, Wilson, PW, Rosenberg, IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N. Engl. J. Med. 1999; 340: 1449–54.CrossRefGoogle ScholarPubMed
12Motti, C, Gnasso, A, Bernardini, S, Massoud, R, Pastore, A, Rampa, P, Federici, G, Cortese, C.Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine and other risk factors for vascular disease. Atherosclerosis 1998; 139: 377–83.CrossRefGoogle ScholarPubMed
13Molloy, AM, Scott, JM. Folates and prevention of disease. (this issue)Google Scholar
14Bostom, AG, Shemin, D, Lapane, KL, Nadeau, MR, Sutherland, P, Chan, J, Rozen, R, Yoburn, D, Jacques, PT, Selhub, J, Rosenberg, IH. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 1996; 123: 193–202.CrossRefGoogle ScholarPubMed
15Bostom, AG, Culleton, BF. Hyperhomocysteinemia in chronic renal disease. J. Am. Soc. Nephrol. 1999; 10: 891–900.CrossRefGoogle ScholarPubMed
16Fodinger, M, Mannhalter, C, Wolfl, G, pabinger, I, Muller, E, Schmid, R, Horl, WH, Sunder-Plassmann, G.Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int. 1997; 52: 517–23.CrossRefGoogle Scholar
17Lee, HA, Choi, JS, Ha, KS, Yang, DH, Chang, SK, Hong, SY. Influence of 5, 10-methylenetetrahydrofolate reductase gene polymorphism on plasma homocysteine concentration in patients with end-stage renal disease. Am. J. Kidney Dis. 1999; 34: 259–63.CrossRefGoogle Scholar
18Fodinger, M, Buchmayer, H, Heinz, G, Papagiannopoulos, M, Kletzmayr, J, Rasoul-Rockenschaub, S, Horl, WH, Sunder-Plassmann, G.Effect of MTHFR 1298A → C and MTHFR 677C → T genotypes on total homocysteine, folate, and vitamin B(12) plasma concentrations in kidney graft recipients. J. Am. Soc Nephrol. 2000; 11: 1918–25.Google Scholar
19Gerdes, LU, Klausen, IC, Sihm, I, Faergeman, O, Apolipoprotein, E.polymorphism in a Danish population compared to findings in forty-five other study populations around the world. Genet. Epidemiol. 1992; 9: 155–67.CrossRefGoogle Scholar
20Kesaniemi, YA, Ehnholm, C, Miettinen, TA. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J. Clin. Invest. 1987; 80: 578–81.CrossRefGoogle Scholar